

## Review Form 1.6

Journal Name:	<a href="#">Journal of Pharmaceutical Research International</a>
Manuscript Number:	Ms_JPRI_79689
Title of the Manuscript:	SPIRONOLACTONE IN DERMATOLOGY
Type of the Article	review

### **General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journaljpri.com/index.php/JPRI/editorial-policy>)

### **PART 1: Review Comments**

	<b>Reviewer's comment</b>	<b>Author's comment</b> (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Compulsory</b> REVISION comments		
<b>Minor</b> REVISION comments	<p>In this review, the use of spironolactone in different skin diseases is summarized to apply this drug in daily clinical practice.</p> <p>The first publication regarding spironolactone was published in the JADV in 1991 with the title: Spironolactone in dermatologic therapy: (James C. Shaw, JAAD 1991, 24,/2, 236-243).</p> <p>Since the review points to the benefits of therapy, I support its appearance.</p> <p><b>Proposed changes:</b>  <b>Page 3</b>, line 2: dehydroepiandrosterone sulphate (DHEA) should be changed as : (DHEA-S).  <b>Page 4</b> last paragraph:                      development of acne. In addition, sebaceous glands have more steroid enzymes to convert dehydroepiandrosterone (DHEA) dehydroepiandrosterone sulfite and androstenedione to                      I suggest:                      development of acne. In addition, sebaceous glands have more steroid enzymes to convert DHEA, DHEA-S, and androstenedione to</p> <p><b>Page5</b>, line 4:                      The main adverse effects are hyperkalemia <del>or hyperkalemia</del>, which is more frequent in.</p> <p>It would also be helpful to describe the data on the dosing of the spironolactone.</p>	
<b>Optional/General</b> comments		

**Review Form 1.6**

**PART 2:**

	<b>Reviewer's comment</b>	<b>Author's comment</b> <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
<b>Are there ethical issues in this manuscript?</b>	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

**Reviewer Details:**

Name:	<b>János Hunyady</b>
Department, University & Country	<b>University of Debrecen, Hungary</b>